Attached files
| file | filename |
|---|---|
| 8-K - PHMD 8K - Gadsden Properties, Inc. | form_8-k.htm |
EXHIBIT 99.1
|
Contacts:
|
LHA
Kim Sutton Golodetz
212-838-3777
Kgolodetz@lhai.com
Bruce Voss, 310-691-7100
Bvoss@lhai.com
|
PhotoMedex, Inc.
Dennis McGrath, Chief Financial Officer
215-619-3287
info@photomedex.com
|
|
|
@LHA_IR_PR
|
PHOTOMEDEX REPORTS FIRST QUARTER 2012 FINANCIAL RESULTS
Revenues increased 45% over the same period in 2011, consumer revenues increased 26%
MONTGOMERYVILLE, Pa. (May 10, 2012) – PhotoMedex, Inc. (NASDAQ: PHMD) today reported financial results for the three months ended March 31, 2012. Financial highlights of the 2012 first quarter include:
|
·
|
Revenues of $50.3 million, an increase of 45% compared with the prior-year first quarter and an increase of 75% sequentially
|
|
·
|
Consumer revenues of $42.2 million, an increase of 26% compared with the prior-year first quarter and an increase of 63% sequentially
|
|
·
|
Gross profit of $39.0 million, an increase of 37% or $10.5 million compared with the first quarter of 2011
|
|
·
|
Gross margin of 77.7% compared with 82.1% in the prior-year first quarter, reflecting the inclusion of revenues from the pre-merged PhotoMedex
|
|
·
|
Income before taxes, litigation expense and one-time expenses of $7.8 million, net income of $4.9 million
|
|
·
|
Litigation and one-time expenses of $2.7 million
|
|
·
|
Adjusted income of $10.7 million or $0.56 per diluted share
|
On December 13, 2011 Radiancy, Inc. became a majority owned subsidiary of PhotoMedex in a reverse merger. In accordance with generally accepted accounting principles (GAAP), Radiancy is deemed to be the financial acquirer for financial statement purposes and therefore the related consolidated statements of operations for the periods prior to December 31, 2011 do not include activity from the pre-merged PhotoMedex prior to the date of merger.
Reported Financial Results
Revenues for the first quarter of 2012 were $50.3 million, an increase of 45% over the same period last year. Included in this amount is $7.1 million in revenues from pre-merged PhotoMedex. This compares with revenues for the first quarter of 2011 of $34.7 million, which included no revenues from pre-merged PhotoMedex.
Net income for the first quarter of 2012 was $4.9 million, or $0.26 per diluted per share, which included $1.8 million in stock-based compensation expense, $1.3 million in depreciation and amortization expenses, $1.8
million in litigation expenses and $0.5 million in other one-time charges. This compares with net income for the first quarter of 2011 of $8.1 million, or $0.68 per diluted share, which included $0.1 million in stock-based compensation expense, $0.1 million in depreciation and amortization expenses and $0.7 million in litigation expenses.
As of March 31, 2012, the Company had cash and cash equivalents of $23.5 million. On April 27, 2012, the Company raised $40.0 million in gross proceeds from concurrent registered offerings of 3,023,432 shares of common stock, yielding net proceeds of $37.8 million.
On a pro forma basis, had the merger been completed on January 1, 2011, revenues for the three months ended March 31, 2011 would have been $42.9 million, gross profit would have been $32.1 million and net income would have been $6.3 million.
Management expects revenues for the second quarter of 2012 to exceed $53 million.
Dr. Dolev Rafaeli, PhotoMedex CEO, commented, “Led by a 26% increase in consumer sales, the first quarter marks the third year of quarter-over-quarter double-digit revenue growth, an accomplishment we are very proud to note and one we expect to continue. We are planning to expand our reach for no!no!™, Omnilux™, Lumiere™ and LHE™ brands and other consumer products into new geographies throughout the coming year.”
“We also are focused on applying our marketing expertise to PhotoMedex’s legacy products, the XTRAC® for the treatment of psoriasis and the Neova® brands of DNA repair skin care products. During the first quarter we began pilot television commercials for XTRAC® in select U.S. cities, and we are in the process of fine-tuning our message while broadening the XTRAC® direct-to-consumer reach to additional markets. We are also pleased with the progress we have made in applying our direct-to-consumer platform to the Neova brand.”
Dr. Rafaeli concluded, “The first quarter of 2012 was the first full quarter of combined operations and financial results following the merger in December. The business integration has gone smoothly and on plan, and we are pleased with the successful execution and the growth prospects for the combined company.”
A reconciliation of non-GAAP financial measures to GAAP financial measures, and a presentation of the most directly comparable GAAP financial measures are included below.
Non-GAAP Measures
To supplement PhotoMedex’s consolidated financial statements presented in accordance with GAAP, PhotoMedex provides certain non-GAAP measures of financial performance. These non-GAAP measures include non-GAAP adjusted income and non-GAAP adjusted income per share.
PhotoMedex’s reference to these non-GAAP measures should be considered in addition to results prepared under current accounting standards, but are not a substitute for, nor superior to, GAAP results. These non-GAAP measures are provided to enhance investors' overall understanding of PhotoMedex’s current financial performance and to provide further information for comparative purposes.
Specifically, the Company believes the non-GAAP measures provide useful information to both management and investors by isolating certain expenses, gains and losses that may not be indicative of the Company’s core operating results and business outlook. In addition, PhotoMedex believes non-GAAP measures enhance the
comparability of results against prior periods. Reconciliation to the most directly comparable GAAP measure of all non-GAAP measures included in this press release is as follows:
(Unaudited)
|
Three Months Ended March, 31
|
||||||||
|
(ooo's) except per share amounts
|
2012
|
2011 | * | |||||
|
Net (Loss) Income as reported
|
$ | 4,857 | $ | 8,085 | ||||
|
Adjustments:
|
||||||||
|
Stock-based compensation expense
|
1,753 | 50 | ||||||
|
Depreciation and amortization expense
|
1,332 | 92 | ||||||
|
Investment banking and related costs
|
408 | - | ||||||
|
Litigation expense
|
1,794 | 680 | ||||||
|
Severance and related integration costs
|
80 | - | ||||||
|
Interest expense, net
|
189 | - | ||||||
|
Income tax expense
|
240 | 2,835 | ||||||
|
Non-GAAP adjusted income
|
$ | 10,653 | $ | 11,742 | ||||
|
Fully Diluted Shares outstanding at March 31, 2012
|
18,876 | 18,876 | ||||||
|
Non-GAAP adjusted income per share
|
$ | 0.56 | $ | 0.62 | ||||
*As a result of purchase accounting rules, the operating results of the pre-merged PhotoMedex for the three-month period ended March 31, 2011 are not included in the consolidated statements of operations for the periods ended March 31, 2011.
Conference Call
PhotoMedex will hold a conference call to discuss the Company's first quarter 2012 results and answer questions today, May 10, 2012 beginning at 4:30 p.m. Eastern time.
To participate in the conference call, dial toll free 888-778-8904 or International/toll 913-312-0961 (and confirmation code # 6862422). If you are unable to participate, a replay of the call will be available from Thursday, May 10 at 6:30 p.m. ET until Thursday, May 24, 2012 at 6:30 p.m. ET by dialing toll free 888-203-1112 or International/toll 719-457-0820and using confirmation code # 6862422.
The live broadcast of PhotoMedex, Inc.'s quarterly conference call will be available online by going to www.photomedex.com and clicking on the link to Investor Relations, and at www.streetevents.com. The online replay will be available shortly after the conclusion of the call at those sites.
About PhotoMedex
PhotoMedex is a global skin health company providing integrated disease management and aesthetic solutions to dermatologists, professional aestheticians and consumers. The company provides proprietary products and services that address skin diseases and conditions including psoriasis, vitiligo, acne, actinic keratosis (a precursor to certain types of skin cancer) and photo damage. Its experience in the physician market provides the platform to expand its skin health solutions to spa markets, as well as traditional retail, online and infomercial outlets for home-use products. As a result of its December 2011 merger with Radiancy Inc., PhotoMedex has added a range of home-use devices under the no!no!™ brand, for various indications including hair removal, acne treatment and skin rejuvenation. The company also offers a professional product line for acne clearance, skin tightening, psoriasis care and hair removal sold to physician clinics and spas.
SAFE HARBOR STATEMENT
Some portions of the conference call, particularly those describing PhotoMedex' strategies, operating expense reductions and business plans will contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including any statements of the plans, strategies and objectives of management for future operations; any statements regarding product development, product extensions, product integration or product marketing; any statements regarding continued compliance with government regulations, changing legislation or regulatory environments; any statements of expectation or belief and any statements of assumptions underlying any of the foregoing. In addition, there are risks and uncertainties related to successfully integrating the products and employees of the Company and Radiancy, as well as the ability to ensure continued regulatory compliance, performance and/or market growth. These risks, uncertainties and other factors, and the general risks associated with the businesses of the Company described in the reports and other documents filed with the SEC, could cause actual results to differ materially from those referred to, implied or expressed in the forward-looking statements. The Company cautions readers not to rely on these forward-looking statements. All forward-looking statements are based on information currently available to the Company and are qualified in their entirety by this cautionary statement. The Company anticipates that subsequent events and developments will cause its views to change. The information contained in this conference call speaks as of the date hereof and the Company has or undertakes no obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.
.
-- Financial Statements follow --
PHOTOMEDEX, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(UNAUDITED)
|
Three Months Ended March 31,
|
||||||||
|
(ooo's) except per share amounts
|
2012
|
2011 | * | |||||
|
Revenues
|
$ | 50,273 | $ | 34,741 | ||||
|
Cost of revenues
|
11,234 | 6,222 | ||||||
|
Gross profit
|
$ | 39,039 | $ | 28,519 | ||||
|
Operating expenses:
|
||||||||
|
Selling and marketing
|
25,835 | 14,647 | ||||||
|
General and administrative
|
7,119 | 2,813 | ||||||
|
Research and development and engineering
|
758 | 170 | ||||||
| 33,712 | 17,630 | |||||||
|
Operating income
|
5,327 | 10,889 | ||||||
|
Interest and other financing income (expense), net
|
(230 | ) | 31 | |||||
|
Income before taxes expense
|
5,097 | 10,920 | ||||||
|
Income tax expense
|
(240 | ) | (2,835 | ) | ||||
|
Net income 1
|
$ | 4,857 | $ | 8,085 | ||||
|
Net income per share:
|
||||||||
|
Basic
|
$ | 0.26 | $ | 0.79 | ||||
|
Diluted
|
$ | 0.26 | $ | 0.68 | ||||
|
Shares used in computing net income per share:
|
||||||||
|
Basic
|
18,340 | 10,256 | ||||||
|
Diluted
|
18,876 | 11,819 | ||||||
|
1 Includes: depreciation and amortization
|
1,332 | 92 | ||||||
|
Share-based compensation expense
|
1,753 | 50 | ||||||
*As a result of purchase accounting rules, the operating results of the pre-merged PhotoMedex for the three-month period ended March 31, 2011 are not included in the above consolidated statements of operations for the period ended March 31, 2011.
| PHOTOMEDEX, INC. | ||||||||||||
| CONSOLIDATED STATEMENTS OF REVENUES | ||||||||||||
| (UNAUDITED) | ||||||||||||
|
For the three months ended:
|
||||||||||||
|
Mar 31, 2012
|
Dec 31, 2011
|
Mar 31, 2011
|
||||||||||
|
Consumer:
|
||||||||||||
|
Direct
|
$ | 31,516 | $ | 17,957 | $ | 20,063 | ||||||
|
Distributors
|
4,183 | 3,123 | 8,860 | |||||||||
|
Retailer and home shopping channels
|
6,502 | 4,783 | 4,704 | |||||||||
|
sub-total
|
42,201 | 25,863 | 33,627 | |||||||||
|
Physician Recurring
|
||||||||||||
|
XTRAC treatments
|
1,679 | 298 | - | |||||||||
|
Skin care
|
2,165 | 385 | - | |||||||||
|
Other
|
1,229 | 147 | - | |||||||||
|
sub-total
|
5,073 | 830 | - | |||||||||
|
Professional
|
2,999 | 2,057 | 1,114 | |||||||||
|
Total Revenues
|
$ | 50,273 | $ | 28,750 | $ | 34,741 | ||||||
|
PHOTOMEDEX, INC.
|
||||||||
|
CONDENSED CONSOLIDATED BALANCE SHEETS
|
||||||||
|
(UNAUDITED)
|
||||||||
|
Mar 31, 2012
|
Dec 31, 2011
|
|||||||
|
Assets
|
||||||||
|
Cash and cash equivalents
|
$ | 23,548 | $ | 16,549 | ||||
|
Accounts receivable, net
|
18,780 | 12,393 | ||||||
|
Inventories
|
18,738 | 19,208 | ||||||
|
Property and equipment, net
|
5,219 | 5,324 | ||||||
|
Other assets
|
91,401 | 92,089 | ||||||
|
Total Assets
|
$ | 157,686 | $ | 145,563 | ||||
|
Liabilities and Stockholders' Equity
|
||||||||
|
Accounts payable and accrued liabilities
|
$ | 31,495 | $ | 26,900 | ||||
|
Other current liabilities
|
2,680 | 1,948 | ||||||
|
Bank and lease notes payable
|
1,563 | 2,232 | ||||||
|
Other liabilities
|
3,140 | 2,405 | ||||||
|
Stockholders' equity
|
118,808 | 112,078 | ||||||
|
Total Liabilities and Stockholders' Equity
|
$ | 157,686 | $ | 145,563 | ||||
PHOTOMEDEX, INC.
CONDENSED STATEMENTS OF CASH FLOWS
(UNAUDITED)
|
For the three months ended March 31,
|
||||||||
|
2012
|
2011 | * | ||||||
|
CASH FLOWS FROM OPERATING ACTIVITIES:
|
||||||||
|
Net income
|
$ | 4,857 | 8,085 | |||||
|
Adjustments to reconcile net income (loss) to
|
||||||||
|
net cash provided by operating activities--
|
||||||||
|
Depreciation and amortization
|
1,332 | 92 | ||||||
|
Provision for doubtful accounts
|
714 | 997 | ||||||
|
Provision for sales returns
|
10,566 | 3,279 | ||||||
|
Stock based compensation
|
1,753 | 50 | ||||||
|
Deferred income taxes
|
2,027 | 1,956 | ||||||
|
Changes in assets and liabilities:
|
||||||||
|
(Increase) decrease in--
|
||||||||
|
Current assets
|
(8,598 | ) | (12,063 | ) | ||||
|
Current liabilities
|
(4,503 | ) | 2,211 | |||||
|
Net cash provided by operating activities
|
8,148 | 4,607 | ||||||
|
CASH FLOWS FROM INVESTING ACTIVITIES:
|
||||||||
|
Lasers placed into service
|
(366 | ) | - | |||||
|
Purchases of PP&E, net
|
(96 | ) | (91 | ) | ||||
|
Other
|
(70 | ) | (61 | ) | ||||
|
Net cash used in investing activities
|
(532 | ) | (152 | ) | ||||
|
CASH FLOWS FROM FINANCING ACTIVITIES:
|
||||||||
|
Proceeds from exercise of options/issuance of warrants
|
125 | - | ||||||
|
Repayment of debt
|
(737 | ) | - | |||||
|
Net cash used in financing activities
|
(612 | ) | - | |||||
|
EFFECT OF EXCHANGE RATE CHANGES ON CASH
|
(5 | ) | - | |||||
|
NET INCREASE IN CASH AND CASH EQUIVALENTS
|
6,999 | 4,455 | ||||||
|
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD
|
16,549 | 7,581 | ||||||
|
CASH AND CASH EQUIVALENTS, END OF PERIOD
|
$ | 23,548 | $ | 12,036 | ||||
*As a result of purchase accounting rules, the operating results of the pre-merged PhotoMedex for three- months ended March 31, 2011 are not included in the above condensed statements of cash flows for the period ended March 31, 2011.